Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer

Barbara L. Weber, Charles Vogel, Stephen Jones, Harold Harvey, Laura Hutchins, Joseph Bigley, John Hohneker

Research output: Contribution to journalArticlepeer-review

185 Scopus citations


Purpose: We evaluated single-agent intravenous (IV) vinorelbine as first- and second-line treatment for advanced breast cancer (ABC) in patients who were not resistant to anthracyclines. Objective tumor response (TR) and toxicity were assessed. Patients and Methods: A total of 107 women were enrolled onto this multicenter, nonrandomized, open-label phase II study. Patients were stratified into first- and second-line treatment groups, based on prior treatment history. Vinorelbine was initially given at 30 mg/m2/wk, with dose modification for toxicity as indicated. Therapy was continued until disease progression or severe toxicity mandated withdrawal or until the patient asked to be removed from the study. Results: The objective response rate for all patients was 34% (95% confidence interval [CI], 25% to 44%): 35% (95% CI, 23% to 48%) for first-line patients and 32% (95% CI, 20% to 47%) for second-line patients. Nine first-line and three second-line patients obtained a complete response (CR). The median duration of objective response was 34 weeks in both groups. The overall survival durations of first- and second- line patients were 67 weeks and 62 weeks, respectively. Granulocytopenia was the predominant dose-limiting toxicity. Two patients died on study as a result of granulocytopenic sepsis. Conclusion: Single-agent vinorelbine is an effective and well-tolerated agent for first- and second-line therapy of ABC. The results of this study confirm the findings of similar international trials and suggest vinorelbine should be considered a valid treatment option for patients with ABC and a potential component in future combination regimens for this disease.

Original languageEnglish (US)
Pages (from-to)2722-2730
Number of pages9
JournalJournal of Clinical Oncology
Issue number11
StatePublished - Nov 1995

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer'. Together they form a unique fingerprint.

Cite this